The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.

Merck shares have jumped since the drug maker said molnupiravir cuts the risk of COVID hospitalization or death by about 50%.

The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.

Year-to-date, shares of BioNTech, Moderna, and Pfizer have surged 357%, 275%, and 28%, respectively.

"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine each year from 2022-2038," BofA argued.

"To justify $200 billion in value, one has to assume 1 to 1.5 billion doses of COVID-19 vaccine each year from 2022-2038," BofA argued.

Moderna, the almost 11 year old company that created a 95% effective pandemic ending vaccine in less than a year, is now worth more than Merck.

Alexion Therapeutics, which is set to be acquired by AstraZeneca, will be replaced by Moderna in the market-cap weighted index.

The CDC's guidance to pause the use of J&J's COVID vaccine came following reports of 6 rare blood clots in patients after receiving the single-dose.

Moderna and Johnson & Johnson's vaccines are approved for adults over 18, while the vaccine from Pfizer and BioNTech is approved for individuals over 16.

The company during its earnings call also announced the September departure of Tal Zaks, its chief medical officer.

Moderna gained 12% after a report its vaccine likely protects against new COVID-19 strains. Moderna reached an intraday high of $US147.43 Monday morning. The biotech company will begin testing a booster against the variant first found in South Africa. Watch Moderna trade live here . Shares of Moderna gained as […]

Moderna slumped as much as 6.2% on Friday as investors sold off on encouraging news regarding the company’s coronavirus vaccine. A panel of Food and Drug Administration experts recommended the vaccine be approved for emergency use on Thursday, a key step that will set the shot up for distribution in […]

Strong preliminary data results from Moderna’s COVID-19 vaccine has spurred a selloff in rival vaccine developers Pfizer, BioNTech, and AstraZeneca. Moderna said on Monday that its COVID-19 vaccine candidate demonstrated an efficacy rate of 94.5% in a trial of more than 30,000 patients. Last week, Pfizer and its partner BioNTech […]

Shares in Moderna rose 9% in pre-market trading on Monday after an independent health board said its COVID-19 vaccine is almost 95% effective. Moderna plans to apply for Emergency Use Authorization with the US Food and Drug Administration (FDA) in the coming weeks. Visit Business Insider’s homepage for more stories. […]

US stocks rose Wednesday amid investor optimism around further economic stimulus and the prospect of a coronavirus vaccine. The benchmark S&P 500 closed less than 0.2% from a record. It last reached an all-time high on Feb. 19, prior to the coronavirus crash. Shares of Moderna spiked after President Trump […]

US stocks rose Wednesday as investors reacted to positive coronavirus vaccine news. Shares of Moderna spiked after President Trump announced the US government will by 100 million doses of its coronavirus vaccine. Tesla shares gained after the company announced a five-for-one stock split. Oil prices climbed after a report suggested […]